Discover investment opportunities in Biotech Penny Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Penny Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Biotech Penny Stocks using our Smart AI Filter.
7 stocks found for "Biotech Penny Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.13 Risk measure | ±91.9% Price volatility | -5.0 Valuation | 0.00% Annual yield | |||
0.78 Risk measure | ±100.0% Price volatility | -5.7 Valuation | 0.00% Annual yield | |||
0.76 Risk measure | ±41.4% Price volatility | 25.6 Valuation | 0.00% Annual yield | |||
2.30 Risk measure | ±100.0% Price volatility | -1.9 Valuation | 0.00% Annual yield | |||
1.25 Risk measure | ±78.9% Price volatility | -3.7 Valuation | 0.00% Annual yield | |||
0.62 Risk measure | ±66.5% Price volatility | -5.6 Valuation | 0.00% Annual yield | |||
1.70 Risk measure | ±100.0% Price volatility | -0.6 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What stock characteristics make INO and ADMP appealing to biotech penny stock investors?
A: INO and ADMP attract investors due to their focus on innovative biotechnology developments at a low entry price. As penny stocks, they offer high growth potential, but come with significant volatility and financial instability risks. Investors often consider both companies' pipelines and regulatory updates to assess their progress and market potential.
Q: Why might an investor be interested in CTXR's performance in today's market?
A: CTXR appeals to investors due to its focus on cutting-edge, niche medical treatments. It operates within the volatile and rapidly-evolving biotech sector, where successful products can lead to significant capital appreciation. However, investors should consider market trends and clinical trial outcomes to gauge its performance potential.
Q: In what ways can the biotech sector influence the volatility of stocks like OCNG and ATOS?
A: OCNG and ATOS experience volatility due to the biotech sector’s sensitivity to regulatory approvals, clinical trial results, and competitive dynamics. Investors closely monitor scientific breakthroughs and FDA decisions, which can significantly influence stock prices either positively or negatively.
Q: How can AVXL's advancement in neurological treatments impact its market appeal?
A: AVXL focuses on developing therapies for central nervous system disorders, which positions it strongly in a sector with robust demand. Success in clinical trials may enhance its market appeal, but uncertain regulatory results and high R&D costs pose risks. Investors examine trial updates and investor relations for insights.
Q: What dividend prospects exist for biotech penny stocks like MNKD and their impact on investment decisions?
A: Generally, biotech penny stocks like MNKD do not offer dividends due to their focus on reinvestment into research, pushing growth prospects instead of immediate returns. Investors evaluating these stocks often prioritize long-term appreciation over income potential, considering each company's pipeline success and market potential.
Q: Why do investors need to pay attention to clinical trial phases for stocks like CALA and ATHX?
A: Clinical trial phases greatly impact prices of CALA and ATHX, as advancements lead to value upticks while setbacks can cause declines. Investors assess trial results and FDA feedback for indications of a product’s market viability and timeline for commercialization, which are critical in investment decisions.
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read moreCEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector.
Read more